Navigation Links
Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin

ay 2007, Herceptin received European approval for use in combination with anastrazole for the treatment of women with advanced HER2-positive breast cancer that is also hormone receptor positive.

In the early setting, Herceptin is approved for use following standard (adjuvant) chemotherapy. Herceptin is marketed in the United States by Genentech, in Japan by Chugai and internationally by Roche. Since 1998, Herceptin has been used to treat nearly 400,000 HER2-positive breast cancer patients worldwide.

About Roche Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, a market leader in virology and active in other major therapeutic areas such as autoimmune diseases, inflammation, metabolism and central nervous system. In 2006 sales by the Pharmaceuticals Division totalled 33.3 billion Swiss francs, and the Diagnostics Division posted sales of 8.7 billion Swiss francs. Roche employs roughly 75,000 worldwide and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai. Additional information about the Roche Group is available on the Internet at www.roche.com.

All trademarks used or mentioned in this release are legally protected.

- About Roche: www.roche.com - About Genentech: www.gene.com - About cancer: www.health-kio
'"/>





Page: 1 2 3 4 5

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
11. Investigational Study Evaluates the Effectiveness of Aripiprazole in Adolescents With Schizophrenia
Post Your Comments:
(Date:5/28/2015)... -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) announces ... June 4 at 1:00 p.m. ET / 10:00 a.m. ... Internet.  Simply log onto our website listed above. If ... a replay of the webcast will be available for ... ABOUT ISIS PHARMACEUTICALS, INC. Isis is exploiting its leadership ...
(Date:5/28/2015)... , May 28, 2015  CytomX, a biotechnology company ... announced that Sean McCarthy , D. Phil., chief ... 2015 Global Healthcare Conference in New ... June 2, 2015. Dr. McCarthy will provide an overview ... immunotherapy and Probody drug conjugate programs. About ...
(Date:5/28/2015)... 2015 Research and ... of Jain PharmaBiotech,s new report  "Personalized Medicine ... offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The aim ... to match the right drug to the ... to design the appropriate treatment for a ...
Breaking Medicine Technology:Webcast Alert: Akcea Therapeutics Conference Call 2Webcast Alert: Akcea Therapeutics Conference Call 3Global Personalized Medicine Report 2015-2024 - Scientific and Commercial Aspects 2Global Personalized Medicine Report 2015-2024 - Scientific and Commercial Aspects 3
... 1, 2011 /PRNewswire-USNewswire/ – CoMeD – On ... Programme (UNEP) distributed a revised text for ... mercury-free drugs were gratified to see pharmaceuticals listed in ... treaty. The Coalition for Mercury-free Drugs ...
... Reportlinker.com announces that a new market research ... Dry Powder Inhalation: Devices, Drugs, ... http://www.reportlinker.com/p0581176/Dry-Powder-Inhalation-Devices-Drugs-Therapeutics-Markets-and-Forecasts .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ... device design are creating new opportunities for ...
Cached Medicine Technology:Global Mercury Treaty May Include Ban on Mercury in Medicine 2Global Mercury Treaty May Include Ban on Mercury in Medicine 3Dry Powder Inhalation: Devices, Drugs, Therapeutics, Markets and Forecasts 2Dry Powder Inhalation: Devices, Drugs, Therapeutics, Markets and Forecasts 3
(Date:5/29/2015)... The world of dentistry had an image problem in ... who dispense pain to people unfortunate enough to need to ... came to surgeries, people would have to spend a lot ... back in the 20th Century now. Nowadays one need only ... Sheepshead Bay neighborhood of Brooklyn, New York to see ...
(Date:5/29/2015)... The 3D Certificate program is for senior managers, ... and engineering aspects of evaluating 3D technology. Any company ... in their existing 3D investment, or getting an education ... in manufacturing in various fields, will benefit greatly from ... that cover the following topics: state of the art ...
(Date:5/29/2015)... 2015 Acoustiblok recently resolved a noisy ... for Three Valleys Municipal Water District (Three Valleys MWD) ... working on the project said, “The new Acoustiblok All ... and are much better looking than the temporary barriers. ... helped us throughout the process, and the customer service ...
(Date:5/28/2015)... 29, 2015 Medical Device Cybersecurity ... Approaches, **FDAnews Webinar**, June 23, 2015 — 1:00 ... , Network connectivity opens up a wealth of ... a minefield of potential liabilities. Devices transmit data ... can manufacturers be sure the information doesn’t fall ...
(Date:5/28/2015)... 28, 2015 Today the National Resident ... for the 2015 Main Residency Match®. A record-number ... were filled when the matching algorithm was processed. ... during the Match Week Supplemental Offer and Acceptance Program® ... are pleased with the outcome of the 2015 Main ...
Breaking Medicine News(10 mins):Health News:Brooklyn Dentist Delivers Comfortable Care Through High Technology 2Health News:Brooklyn Dentist Delivers Comfortable Care Through High Technology 3Health News:Brooklyn Dentist Delivers Comfortable Care Through High Technology 4Health News:Second Cohort in 3D Certificate Program to Launch in August by Graduate School 2Health News:Second Cohort in 3D Certificate Program to Launch in August by Graduate School 3Health News:Acoustiblok® Quiets Well Motor Noise for California Water District 2Health News:Acoustiblok® Quiets Well Motor Noise for California Water District 3Health News:Acoustiblok® Quiets Well Motor Noise for California Water District 4Health News:Acoustiblok® Quiets Well Motor Noise for California Water District 5Health News:FDAnews Announces — Medical Device Cybersecurity Quality Assurance: Requirements, Best Practices and Innovative Approaches Webinar, June 23, 2015 2Health News:FDAnews Announces — Medical Device Cybersecurity Quality Assurance: Requirements, Best Practices and Innovative Approaches Webinar, June 23, 2015 3Health News:NRMP Releases Results and Data: 2015 Residency Match: Record Number of Positions Filled 2Health News:NRMP Releases Results and Data: 2015 Residency Match: Record Number of Positions Filled 3
... 24th January 2008 - The main regulators of the ... highly involved in a large range of immune diseases. ... play a critical role in the onset of type ... Dr. Ciriaco Piccirillo, a researcher in the Department of ...
... new treatments for diabetes, researchers say , , THURSDAY, Jan. 24 ... managed to locate stem cells in the pancreas -- in ... in humans, they could pave the way for dramatic new ... the body could once again produce its own insulin. Until ...
... of consumer statutes, breach of warranty and, unjust enrichment; Damages ... of $5 billion last year, mostly paid through Medicare, Medicaid, ... other federal drug programs and private insurance, JACKSONVILLE, Fla., ... announced that they have filed a lawsuit against,Merck & Company ...
... ... to Your Neighborhood, WASHINGTON, Jan. 24 The national nonprofit,Home ... home safety exhibit -- The Great Safety Adventure.,In an effort to ... been touring the country since 1999 stopping at,elementary schools and Lowe,s ...
... During Super Bowl, WASHINGTON, Jan. 24 ... (ONDCP) is launching its first major,Federal effort to ... public awareness campaign will begin with advertising during ... TV advertising targeting,parents in nearly two years. The ...
... ... a healthy lifestyle, NEW YORK, Jan. 24 Aflac (NYSE: ... Girl. With 10 events nationwide, ranging,from 5K/10K, duathlon and triathlons, Aflac ... active lifestyle., To illustrate the collective commitment to this partnership, ...
Cached Medicine News:Health News:Deficient regulators in the immune system responsible for type 1 diabetes 2Health News:Stem Cells Finally Found in Pancreas 2Health News:Stem Cells Finally Found in Pancreas 3Health News:Lawsuit Filed in Florida Federal Court Over Marketing of Vytorin and Zetia By Merck and Schering-Plough 2Health News:Lawsuit Filed in Florida Federal Court Over Marketing of Vytorin and Zetia By Merck and Schering-Plough 3Health News:The Great Safety Adventure(R) Traveling Home Safety Exhibit Kicks Off Tenth Anniversary Tour 2Health News:The Great Safety Adventure(R) Traveling Home Safety Exhibit Kicks Off Tenth Anniversary Tour 3Health News:ONDCP Launches First Major Initiative to Combat Teen Prescription Drug Abuse 2Health News:ONDCP Launches First Major Initiative to Combat Teen Prescription Drug Abuse 3Health News:ONDCP Launches First Major Initiative to Combat Teen Prescription Drug Abuse 4Health News:Aflac to Sponsor Iron Girl 2Health News:Aflac to Sponsor Iron Girl 3
Lyphochek Benzo/TCA Control Set A is ideal for monitoring HPLC methods for identification and quantitation of benzodiazepines and tricyclic antidepressant drugs....
Lyphochek Whole Blood Metals Control contains the major heavy metals of toxicological and environmental importance for whole blood analysis....
Lyphochek Whole Blood Control is a unique product designed to monitor immunosuppressants, red cell folate and lead in whole blood assays. This control has three critical levels for each analyte and i...
qUAntify Plus Control is a combination urine dipstick and microscopic control. The control is available in either 12 mL centrifuge tubes or 120 mL flip-top squeeze bottles....
Medicine Products: